#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=Designed scaffolds should be biocompatible and biodegradable , capable of producing an extracellular matrix ( ECM ) by supporting the cell ’s adhesion and proliferation .
3-1	17-25	Designed	object[3]	new[3]	coref	6-8[0_3]
3-2	26-35	scaffolds	object[3]	new[3]	_	_
3-3	36-42	should	_	_	_	_
3-4	43-45	be	_	_	_	_
3-5	46-59	biocompatible	_	_	_	_
3-6	60-63	and	_	_	_	_
3-7	64-77	biodegradable	_	_	_	_
3-8	78-79	,	_	_	_	_
3-9	80-87	capable	_	_	_	_
3-10	88-90	of	_	_	_	_
3-11	91-100	producing	_	_	_	_
3-12	101-103	an	object[4]	new[4]	appos	3-16[0_4]
3-13	104-117	extracellular	object[4]	new[4]	_	_
3-14	118-124	matrix	object[4]	new[4]	_	_
3-15	125-126	(	_	_	_	_
3-16	127-130	ECM	object	giv	_	_
3-17	131-132	)	_	_	_	_
3-18	133-135	by	_	_	_	_
3-19	136-146	supporting	_	_	_	_
3-20	147-150	the	abstract[7]|abstract[8]	new[7]|new[8]	ana|coref|ana|coref	4-1[0_8]|7-13[46_7]|4-1[0_8]|7-13[46_7]
3-21	151-155	cell	place[6]|abstract[7]|abstract[8]	new[6]|new[7]|new[8]	coref	5-45[0_6]
3-22	156-158	’s	place[6]|abstract[7]|abstract[8]	new[6]|new[7]|new[8]	_	_
3-23	159-167	adhesion	abstract[7]|abstract[8]	new[7]|new[8]	_	_
3-24	168-171	and	abstract[8]	new[8]	_	_
3-25	172-185	proliferation	abstract[8]|event	new[8]|new	coref	5-45[32_0]
3-26	186-187	.	_	_	_	_

#Text=They should also have porosity to promote nutrient transportation , and their mechanical properties should be similar to native tissue .
4-1	188-192	They	abstract	giv	ana	4-12
4-2	193-199	should	_	_	_	_
4-3	200-204	also	_	_	_	_
4-4	205-209	have	_	_	_	_
4-5	210-218	porosity	substance	new	_	_
4-6	219-221	to	_	_	_	_
4-7	222-229	promote	_	_	_	_
4-8	230-238	nutrient	substance|abstract[13]	new|new[13]	coref|coref	5-33|5-33
4-9	239-253	transportation	abstract[13]	new[13]	_	_
4-10	254-255	,	_	_	_	_
4-11	256-259	and	_	_	_	_
4-12	260-265	their	abstract|abstract[15]	giv|new[15]	coref|coref|coref|coref	13-3[87_15]|31-34[242_0]|13-3[87_15]|31-34[242_0]
4-13	266-276	mechanical	abstract[15]	new[15]	_	_
4-14	277-287	properties	abstract[15]	new[15]	_	_
4-15	288-294	should	_	_	_	_
4-16	295-297	be	_	_	_	_
4-17	298-305	similar	_	_	_	_
4-18	306-308	to	_	_	_	_
4-19	309-315	native	object[16]	new[16]	coref	13-7[0_16]
4-20	316-322	tissue	object[16]	new[16]	_	_
4-21	323-324	.	_	_	_	_

#Text=To meet these requirements , a high surface area and an interconnected three-dimensional ( 3D ) porous structure with sizes ranging between 200 and 600 μm are essential , while also providing nutrient transfer , waste disposal , cellular infiltration , neovascularization , and cell proliferation .
5-1	325-327	To	_	_	_	_
5-2	328-332	meet	_	_	_	_
5-3	333-338	these	abstract[17]	new[17]	_	_
5-4	339-351	requirements	abstract[17]	new[17]	_	_
5-5	352-353	,	_	_	_	_
5-6	354-355	a	quantity[19]	new[19]	_	_
5-7	356-360	high	quantity[19]	new[19]	_	_
5-8	361-368	surface	place|quantity[19]	new|new[19]	_	_
5-9	369-373	area	quantity[19]	new[19]	_	_
5-10	374-377	and	_	_	_	_
5-11	378-380	an	abstract[21]	new[21]	_	_
5-12	381-395	interconnected	abstract[21]	new[21]	_	_
5-13	396-413	three-dimensional	abstract[21]	new[21]	_	_
5-14	414-415	(	abstract[21]	new[21]	_	_
5-15	416-418	3D	abstract|abstract[21]	new|new[21]	_	_
5-16	419-420	)	abstract[21]	new[21]	_	_
5-17	421-427	porous	abstract[21]	new[21]	_	_
5-18	428-437	structure	abstract[21]	new[21]	_	_
5-19	438-442	with	abstract[21]	new[21]	_	_
5-20	443-448	sizes	abstract[21]|quantity	new[21]|new	_	_
5-21	449-456	ranging	_	_	_	_
5-22	457-464	between	_	_	_	_
5-23	465-468	200	quantity	new	_	_
5-24	469-472	and	_	_	_	_
5-25	473-476	600	quantity	new	_	_
5-26	477-479	μm	person	new	_	_
5-27	480-483	are	_	_	_	_
5-28	484-493	essential	_	_	_	_
5-29	494-495	,	_	_	_	_
5-30	496-501	while	_	_	_	_
5-31	502-506	also	_	_	_	_
5-32	507-516	providing	_	_	_	_
5-33	517-525	nutrient	substance|abstract[27]	giv|new[27]	_	_
5-34	526-534	transfer	abstract[27]	new[27]	_	_
5-35	535-536	,	_	_	_	_
5-36	537-542	waste	abstract[28]	new[28]	_	_
5-37	543-551	disposal	abstract[28]	new[28]	_	_
5-38	552-553	,	_	_	_	_
5-39	554-562	cellular	abstract[29]	new[29]	_	_
5-40	563-575	infiltration	abstract[29]	new[29]	_	_
5-41	576-577	,	_	_	_	_
5-42	578-596	neovascularization	substance	new	_	_
5-43	597-598	,	_	_	_	_
5-44	599-602	and	_	_	_	_
5-45	603-607	cell	place|event[32]	giv|giv[32]	coref|coref|coref|coref	6-18|15-16[0_32]|6-18|15-16[0_32]
5-46	608-621	proliferation	event[32]	giv[32]	_	_
5-47	622-623	.	_	_	_	_

#Text=Natural polymers are preferred materials for producing scaffolds , due to their better overall interactions with various cell types , and their lack of toxicity .
6-1	624-631	Natural	substance[33]	new[33]	coref	7-3[43_33]
6-2	632-640	polymers	substance[33]	new[33]	_	_
6-3	641-644	are	_	_	_	_
6-4	645-654	preferred	_	_	_	_
6-5	655-664	materials	substance	new	ana	6-12
6-6	665-668	for	_	_	_	_
6-7	669-678	producing	_	_	_	_
6-8	679-688	scaffolds	object	giv	_	_
6-9	689-690	,	_	_	_	_
6-10	691-694	due	_	_	_	_
6-11	695-697	to	_	_	_	_
6-12	698-703	their	substance|abstract[37]	giv|new[37]	ana|ana	6-22|6-22
6-13	704-710	better	abstract[37]	new[37]	_	_
6-14	711-718	overall	abstract[37]	new[37]	_	_
6-15	719-731	interactions	abstract[37]	new[37]	_	_
6-16	732-736	with	abstract[37]	new[37]	_	_
6-17	737-744	various	abstract[37]|abstract[39]	new[37]|new[39]	_	_
6-18	745-749	cell	abstract[37]|place|abstract[39]	new[37]|giv|new[39]	coref	7-13
6-19	750-755	types	abstract[37]|abstract[39]	new[37]|new[39]	_	_
6-20	756-757	,	_	_	_	_
6-21	758-761	and	_	_	_	_
6-22	762-767	their	substance|abstract[41]	giv|new[41]	coref|coref	16-4[127_0]|16-4[127_0]
6-23	768-772	lack	abstract[41]	new[41]	_	_
6-24	773-775	of	abstract[41]	new[41]	_	_
6-25	776-784	toxicity	abstract[41]|abstract	new[41]|new	_	_
6-26	785-786	.	_	_	_	_

#Text=However , synthetic polymers are cheaper and allow chemical functionalization to assist cell adhesion despite the immune response .
7-1	787-794	However	_	_	_	_
7-2	795-796	,	_	_	_	_
7-3	797-806	synthetic	substance[43]	giv[43]	coref	8-1[48_43]
7-4	807-815	polymers	substance[43]	giv[43]	_	_
7-5	816-819	are	_	_	_	_
7-6	820-827	cheaper	_	_	_	_
7-7	828-831	and	_	_	_	_
7-8	832-837	allow	_	_	_	_
7-9	838-846	chemical	abstract[44]	new[44]	_	_
7-10	847-864	functionalization	abstract[44]	new[44]	_	_
7-11	865-867	to	_	_	_	_
7-12	868-874	assist	_	_	_	_
7-13	875-879	cell	place|abstract[46]	giv|giv[46]	coref|coref|coref|coref	9-12|15-12[123_46]|9-12|15-12[123_46]
7-14	880-888	adhesion	abstract[46]	giv[46]	_	_
7-15	889-896	despite	_	_	_	_
7-16	897-900	the	abstract[47]	new[47]	_	_
7-17	901-907	immune	abstract[47]	new[47]	_	_
7-18	908-916	response	abstract[47]	new[47]	_	_
7-19	917-918	.	_	_	_	_

#Text=The preferred synthetic polymers used for scaffold synthesis include poly(l-lactic acid ) ( PLLA ) , poly(glycolic acid ) ( PGA ) , poly(caprolactone ) ( PCL ) , and poly(lactic- co -glycolic ) acid ( PLGA ) .
8-1	919-922	The	substance[48]	giv[48]	coref	9-3[56_48]
8-2	923-932	preferred	substance[48]	giv[48]	_	_
8-3	933-942	synthetic	substance[48]	giv[48]	_	_
8-4	943-951	polymers	substance[48]	giv[48]	_	_
8-5	952-956	used	_	_	_	_
8-6	957-960	for	_	_	_	_
8-7	961-969	scaffold	abstract|abstract[50]	new|new[50]	_	_
8-8	970-979	synthesis	abstract[50]	new[50]	_	_
8-9	980-987	include	_	_	_	_
8-10	988-1001	poly(l-lactic	substance[51]	new[51]	_	_
8-11	1002-1006	acid	substance[51]	new[51]	_	_
8-12	1007-1008	)	_	_	_	_
8-13	1009-1010	(	_	_	_	_
8-14	1011-1015	PLLA	_	_	_	_
8-15	1016-1017	)	_	_	_	_
8-16	1018-1019	,	_	_	_	_
8-17	1020-1033	poly(glycolic	_	_	_	_
8-18	1034-1038	acid	_	_	_	_
8-19	1039-1040	)	_	_	_	_
8-20	1041-1042	(	_	_	_	_
8-21	1043-1046	PGA	_	_	_	_
8-22	1047-1048	)	_	_	_	_
8-23	1049-1050	,	_	_	_	_
8-24	1051-1068	poly(caprolactone	_	_	_	_
8-25	1069-1070	)	_	_	_	_
8-26	1071-1072	(	_	_	_	_
8-27	1073-1076	PCL	_	_	_	_
8-28	1077-1078	)	_	_	_	_
8-29	1079-1080	,	_	_	_	_
8-30	1081-1084	and	_	_	_	_
8-31	1085-1097	poly(lactic-	abstract[53]	new[53]	appos	8-37[0_53]
8-32	1098-1100	co	abstract|abstract[53]	new|new[53]	_	_
8-33	1101-1110	-glycolic	abstract[53]	new[53]	_	_
8-34	1111-1112	)	abstract[53]	new[53]	_	_
8-35	1113-1117	acid	abstract[53]	new[53]	_	_
8-36	1118-1119	(	_	_	_	_
8-37	1120-1124	PLGA	abstract	giv	_	_
8-38	1125-1126	)	_	_	_	_
8-39	1127-1128	.	_	_	_	_

#Text=Composites with natural polymers are also available with better hydrophilicity , cell attachment , and biodegradability .
9-1	1129-1139	Composites	object[55]	new[55]	coref	16-1[126_55]
9-2	1140-1144	with	object[55]	new[55]	_	_
9-3	1145-1152	natural	object[55]|substance[56]	new[55]|giv[56]	coref	16-13[0_56]
9-4	1153-1161	polymers	object[55]|substance[56]	new[55]|giv[56]	_	_
9-5	1162-1165	are	_	_	_	_
9-6	1166-1170	also	_	_	_	_
9-7	1171-1180	available	_	_	_	_
9-8	1181-1185	with	_	_	_	_
9-9	1186-1192	better	substance[57]	new[57]	_	_
9-10	1193-1207	hydrophilicity	substance[57]	new[57]	_	_
9-11	1208-1209	,	_	_	_	_
9-12	1210-1214	cell	place|object[59]	giv|new[59]	coref|coref	15-13|15-13
9-13	1215-1225	attachment	object[59]	new[59]	_	_
9-14	1226-1227	,	_	_	_	_
9-15	1228-1231	and	_	_	_	_
9-16	1232-1248	biodegradability	substance	new	coref	13-16
9-17	1249-1250	.	_	_	_	_

#Text=The most used biopolymers are chitosan , alginate ( Alg ) , collagen ( Col ) , gelatin ( Gn ) , silk fibroin ( SF ) , and glycosaminoglycans ( GAGs ) .
10-1	1251-1254	The	substance[61]	new[61]	coref	10-6[62_61]
10-2	1255-1259	most	substance[61]	new[61]	_	_
10-3	1260-1264	used	substance[61]	new[61]	_	_
10-4	1265-1276	biopolymers	substance[61]	new[61]	_	_
10-5	1277-1280	are	_	_	_	_
10-6	1281-1289	chitosan	substance[62]	giv[62]	coref	11-1[0_62]
10-7	1290-1291	,	substance[62]	giv[62]	_	_
10-8	1292-1300	alginate	substance[62]|abstract	giv[62]|new	appos	10-10
10-9	1301-1302	(	substance[62]	giv[62]	_	_
10-10	1303-1306	Alg	substance[62]|abstract	giv[62]|giv	_	_
10-11	1307-1308	)	substance[62]	giv[62]	_	_
10-12	1309-1310	,	substance[62]	giv[62]	_	_
10-13	1311-1319	collagen	substance[62]|organization	giv[62]|new	_	_
10-14	1320-1321	(	substance[62]	giv[62]	_	_
10-15	1322-1325	Col	substance[62]|person	giv[62]|new	_	_
10-16	1326-1327	)	substance[62]	giv[62]	_	_
10-17	1328-1329	,	substance[62]	giv[62]	_	_
10-18	1330-1337	gelatin	substance[62]|substance	giv[62]|new	appos	10-20
10-19	1338-1339	(	substance[62]	giv[62]	_	_
10-20	1340-1342	Gn	substance[62]|substance	giv[62]|giv	_	_
10-21	1343-1344	)	substance[62]	giv[62]	_	_
10-22	1345-1346	,	substance[62]	giv[62]	_	_
10-23	1347-1351	silk	substance[62]|object[69]	giv[62]|new[69]	_	_
10-24	1352-1359	fibroin	substance[62]|object[69]	giv[62]|new[69]	_	_
10-25	1360-1361	(	substance[62]	giv[62]	_	_
10-26	1362-1364	SF	substance[62]|place	giv[62]|new	_	_
10-27	1365-1366	)	substance[62]	giv[62]	_	_
10-28	1367-1368	,	substance[62]	giv[62]	_	_
10-29	1369-1372	and	substance[62]	giv[62]	_	_
10-30	1373-1391	glycosaminoglycans	substance[62]|substance	giv[62]|new	_	_
10-31	1392-1393	(	_	_	_	_
10-32	1394-1398	GAGs	object	new	_	_
10-33	1399-1400	)	_	_	_	_
10-34	1401-1402	.	_	_	_	_

#Text=Chitosan ( CS ) , a natural polymer obtained from the partial deacetylation of chitin , is one of the most common biopolymers on earth .
11-1	1403-1411	Chitosan	substance	giv	appos	11-3
11-2	1412-1413	(	_	_	_	_
11-3	1414-1416	CS	substance	giv	appos	11-6[75_0]
11-4	1417-1418	)	_	_	_	_
11-5	1419-1420	,	_	_	_	_
11-6	1421-1422	a	substance[75]	giv[75]	coref	11-20[79_75]
11-7	1423-1430	natural	substance[75]	giv[75]	_	_
11-8	1431-1438	polymer	substance[75]	giv[75]	_	_
11-9	1439-1447	obtained	_	_	_	_
11-10	1448-1452	from	_	_	_	_
11-11	1453-1456	the	substance[76]	new[76]	_	_
11-12	1457-1464	partial	substance[76]	new[76]	_	_
11-13	1465-1478	deacetylation	substance[76]	new[76]	_	_
11-14	1479-1481	of	substance[76]	new[76]	_	_
11-15	1482-1488	chitin	substance[76]|substance	new[76]|new	_	_
11-16	1489-1490	,	_	_	_	_
11-17	1491-1493	is	_	_	_	_
11-18	1494-1497	one	abstract[78]	new[78]	ana	12-1[0_78]
11-19	1498-1500	of	abstract[78]	new[78]	_	_
11-20	1501-1504	the	abstract[78]|substance[79]	new[78]|giv[79]	coref	13-1[0_79]
11-21	1505-1509	most	abstract[78]|substance[79]	new[78]|giv[79]	_	_
11-22	1510-1516	common	abstract[78]|substance[79]	new[78]|giv[79]	_	_
11-23	1517-1528	biopolymers	abstract[78]|substance[79]	new[78]|giv[79]	_	_
11-24	1529-1531	on	abstract[78]|substance[79]	new[78]|giv[79]	_	_
11-25	1532-1537	earth	abstract[78]|substance[79]|place	new[78]|giv[79]|new	_	_
11-26	1538-1539	.	_	_	_	_

#Text=It is present in the shells of crustaceans such as crab and shrimp .
12-1	1540-1542	It	abstract	giv	_	_
12-2	1543-1545	is	_	_	_	_
12-3	1546-1553	present	_	_	_	_
12-4	1554-1556	in	_	_	_	_
12-5	1557-1560	the	object[82]	new[82]	_	_
12-6	1561-1567	shells	object[82]	new[82]	_	_
12-7	1568-1570	of	object[82]	new[82]	_	_
12-8	1571-1582	crustaceans	object[82]|animal	new[82]|new	_	_
12-9	1583-1587	such	object[82]	new[82]	_	_
12-10	1588-1590	as	object[82]	new[82]	_	_
12-11	1591-1595	crab	object[82]|animal	new[82]|new	_	_
12-12	1596-1599	and	object[82]	new[82]	_	_
12-13	1600-1606	shrimp	object[82]|animal	new[82]|new	_	_
12-14	1607-1608	.	_	_	_	_

#Text=CS has many desirable properties for tissue engineering such as biocompatibility , non-toxicity , and biodegradability .
13-1	1609-1611	CS	abstract	giv	coref	14-1
13-2	1612-1615	has	_	_	_	_
13-3	1616-1620	many	abstract[87]	giv[87]	coref	18-14[149_87]
13-4	1621-1630	desirable	abstract[87]	giv[87]	_	_
13-5	1631-1641	properties	abstract[87]	giv[87]	_	_
13-6	1642-1645	for	abstract[87]	giv[87]	_	_
13-7	1646-1652	tissue	abstract[87]|object|abstract[89]	giv[87]|giv|new[89]	coref|coref|coref|coref	15-6|15-5[120_89]|15-6|15-5[120_89]
13-8	1653-1664	engineering	abstract[87]|abstract[89]	giv[87]|new[89]	_	_
13-9	1665-1669	such	abstract[87]|abstract[89]	giv[87]|new[89]	_	_
13-10	1670-1672	as	abstract[87]|abstract[89]	giv[87]|new[89]	_	_
13-11	1673-1689	biocompatibility	abstract[87]|abstract[89]|abstract	giv[87]|new[89]|new	coref	16-19[132_0]
13-12	1690-1691	,	abstract[87]|abstract[89]	giv[87]|new[89]	_	_
13-13	1692-1704	non-toxicity	abstract[87]|abstract[89]	giv[87]|new[89]	_	_
13-14	1705-1706	,	abstract[87]|abstract[89]	giv[87]|new[89]	_	_
13-15	1707-1710	and	abstract[87]|abstract[89]	giv[87]|new[89]	_	_
13-16	1711-1727	biodegradability	abstract[87]|abstract[89]|substance	giv[87]|new[89]|giv	_	_
13-17	1728-1729	.	_	_	_	_

#Text=CS was used in several tissue-engineering applications involving bone , cartilage , liver , tendons , ligaments and nerves , wound healing , separation membranes , blood anticoagulants , contact lenses , controlled release of drugs , fat-sequestering agent , hydrogel preparations , and food packaging material .
14-1	1730-1732	CS	substance	giv	coref	15-1
14-2	1733-1736	was	_	_	_	_
14-3	1737-1741	used	_	_	_	_
14-4	1742-1744	in	_	_	_	_
14-5	1745-1752	several	abstract[94]	new[94]	coref	20-15[171_94]
14-6	1753-1771	tissue-engineering	abstract|abstract[94]	new|new[94]	_	_
14-7	1772-1784	applications	abstract[94]	new[94]	_	_
14-8	1785-1794	involving	_	_	_	_
14-9	1795-1799	bone	object	new	coref	15-5
14-10	1800-1801	,	_	_	_	_
14-11	1802-1811	cartilage	object	new	_	_
14-12	1812-1813	,	_	_	_	_
14-13	1814-1819	liver	object	new	_	_
14-14	1820-1821	,	_	_	_	_
14-15	1822-1829	tendons	object	new	_	_
14-16	1830-1831	,	_	_	_	_
14-17	1832-1841	ligaments	object	new	_	_
14-18	1842-1845	and	_	_	_	_
14-19	1846-1852	nerves	object	new	_	_
14-20	1853-1854	,	_	_	_	_
14-21	1855-1860	wound	abstract|event[102]	new|new[102]	_	_
14-22	1861-1868	healing	event[102]	new[102]	_	_
14-23	1869-1870	,	_	_	_	_
14-24	1871-1881	separation	abstract|object[104]	new|new[104]	_	_
14-25	1882-1891	membranes	object[104]	new[104]	_	_
14-26	1892-1893	,	_	_	_	_
14-27	1894-1899	blood	substance|substance[106]	new|new[106]	_	_
14-28	1900-1914	anticoagulants	substance[106]	new[106]	_	_
14-29	1915-1916	,	_	_	_	_
14-30	1917-1924	contact	object[107]	new[107]	_	_
14-31	1925-1931	lenses	object[107]	new[107]	_	_
14-32	1932-1933	,	_	_	_	_
14-33	1934-1944	controlled	event[108]	new[108]	_	_
14-34	1945-1952	release	event[108]	new[108]	_	_
14-35	1953-1955	of	event[108]	new[108]	_	_
14-36	1956-1961	drugs	event[108]|substance	new[108]|new	_	_
14-37	1962-1963	,	_	_	_	_
14-38	1964-1980	fat-sequestering	abstract|substance[111]	new|new[111]	_	_
14-39	1981-1986	agent	substance[111]	new[111]	_	_
14-40	1987-1988	,	_	_	_	_
14-41	1989-1997	hydrogel	substance|object[113]	new|new[113]	_	_
14-42	1998-2010	preparations	object[113]	new[113]	_	_
14-43	2011-2012	,	_	_	_	_
14-44	2013-2016	and	_	_	_	_
14-45	2017-2021	food	substance|substance[116]	new|new[116]	_	_
14-46	2022-2031	packaging	abstract|substance[116]	new|new[116]	_	_
14-47	2032-2040	material	substance[116]	new[116]	_	_
14-48	2041-2042	.	_	_	_	_

#Text=CS was evaluated for bone tissue engineering ( BTE ) with good cell adhesion and proliferation observed .
15-1	2043-2045	CS	abstract	giv	coref	16-1
15-2	2046-2049	was	_	_	_	_
15-3	2050-2059	evaluated	_	_	_	_
15-4	2060-2063	for	_	_	_	_
15-5	2064-2068	bone	object|abstract[120]	giv|giv[120]	appos|appos	15-9[0_120]|15-9[0_120]
15-6	2069-2075	tissue	object|abstract[120]	giv|giv[120]	coref	20-17
15-7	2076-2087	engineering	abstract[120]	giv[120]	_	_
15-8	2088-2089	(	_	_	_	_
15-9	2090-2093	BTE	abstract	giv	coref	16-17[131_0]
15-10	2094-2095	)	_	_	_	_
15-11	2096-2100	with	_	_	_	_
15-12	2101-2105	good	abstract[123]	giv[123]	coref	31-34[241_123]
15-13	2106-2110	cell	place|abstract[123]	giv|giv[123]	coref	16-22
15-14	2111-2119	adhesion	abstract[123]	giv[123]	_	_
15-15	2120-2123	and	_	_	_	_
15-16	2124-2137	proliferation	event	giv	coref	16-23
15-17	2138-2146	observed	_	_	_	_
15-18	2147-2148	.	_	_	_	_

#Text=CS composites with different materials such as ceramics , nanofillers , and polymers were evaluated for BTE with excellent biocompatibility and cell proliferation results .
16-1	2149-2151	CS	abstract|object[126]	giv|giv[126]	coref|coref|coref|coref	20-13|27-10[216_126]|20-13|27-10[216_126]
16-2	2152-2162	composites	object[126]	giv[126]	_	_
16-3	2163-2167	with	object[126]	giv[126]	_	_
16-4	2168-2177	different	object[126]|substance[127]	giv[126]|giv[127]	_	_
16-5	2178-2187	materials	object[126]|substance[127]	giv[126]|giv[127]	_	_
16-6	2188-2192	such	object[126]|substance[127]	giv[126]|giv[127]	_	_
16-7	2193-2195	as	object[126]|substance[127]	giv[126]|giv[127]	_	_
16-8	2196-2204	ceramics	object[126]|substance[127]|substance	giv[126]|giv[127]|new	_	_
16-9	2205-2206	,	object[126]|substance[127]	giv[126]|giv[127]	_	_
16-10	2207-2218	nanofillers	object[126]|substance[127]|object	giv[126]|giv[127]|new	coref	21-1[174_0]
16-11	2219-2220	,	object[126]|substance[127]	giv[126]|giv[127]	_	_
16-12	2221-2224	and	object[126]|substance[127]	giv[126]|giv[127]	_	_
16-13	2225-2233	polymers	object[126]|substance[127]|substance	giv[126]|giv[127]|giv	coref	19-9
16-14	2234-2238	were	_	_	_	_
16-15	2239-2248	evaluated	_	_	_	_
16-16	2249-2252	for	_	_	_	_
16-17	2253-2256	BTE	abstract[131]	giv[131]	ana	17-1[0_131]
16-18	2257-2261	with	abstract[131]	giv[131]	_	_
16-19	2262-2271	excellent	abstract[131]|abstract[132]	giv[131]|giv[132]	coref	21-20[177_132]
16-20	2272-2288	biocompatibility	abstract[131]|abstract[132]	giv[131]|giv[132]	_	_
16-21	2289-2292	and	abstract[131]	giv[131]	_	_
16-22	2293-2297	cell	abstract[131]|place|abstract[135]	giv[131]|giv|new[135]	coref|coref|coref|coref	17-16|33-1[260_135]|17-16|33-1[260_135]
16-23	2298-2311	proliferation	abstract[131]|event|abstract[135]	giv[131]|giv|new[135]	coref	31-37
16-24	2312-2319	results	abstract[131]|abstract[135]	giv[131]|new[135]	_	_
16-25	2320-2321	.	_	_	_	_

#Text=It was recognized that amine and hydroxyl groups facilitate the addition of side groups for cell incorporation and recognition in BTE .
17-1	2322-2324	It	abstract	giv	coref	17-21
17-2	2325-2328	was	_	_	_	_
17-3	2329-2339	recognized	_	_	_	_
17-4	2340-2344	that	_	_	_	_
17-5	2345-2350	amine	substance	new	_	_
17-6	2351-2354	and	_	_	_	_
17-7	2355-2363	hydroxyl	organization|person[139]	new|new[139]	coref|coref	17-13[141_139]|17-13[141_139]
17-8	2364-2370	groups	person[139]	new[139]	_	_
17-9	2371-2381	facilitate	_	_	_	_
17-10	2382-2385	the	event[140]	new[140]	_	_
17-11	2386-2394	addition	event[140]	new[140]	_	_
17-12	2395-2397	of	event[140]	new[140]	_	_
17-13	2398-2402	side	event[140]|person[141]	new[140]|giv[141]	coref	23-15[198_141]
17-14	2403-2409	groups	event[140]|person[141]	new[140]|giv[141]	_	_
17-15	2410-2413	for	event[140]|person[141]	new[140]|giv[141]	_	_
17-16	2414-2418	cell	event[140]|person[141]|place|event[143]	new[140]|giv[141]|giv|new[143]	coref|coref	25-9|25-9
17-17	2419-2432	incorporation	event[140]|person[141]|event[143]	new[140]|giv[141]|new[143]	_	_
17-18	2433-2436	and	event[140]|person[141]	new[140]|giv[141]	_	_
17-19	2437-2448	recognition	event[140]|person[141]|abstract[144]	new[140]|giv[141]|new[144]	ana	18-8[0_144]
17-20	2449-2451	in	event[140]|person[141]|abstract[144]	new[140]|giv[141]|new[144]	_	_
17-21	2452-2455	BTE	event[140]|person[141]|abstract[144]|substance	new[140]|giv[141]|new[144]|giv	coref	20-17[173_0]
17-22	2456-2457	.	_	_	_	_

#Text=However , like many other polysaccharides , it presents some disadvantages such as poor mechanical properties , poor solubility in conventional solvents , and poor stability in physiological media due to the high amount of hydrogen bonding .
18-1	2458-2465	However	_	_	_	_
18-2	2466-2467	,	_	_	_	_
18-3	2468-2472	like	_	_	_	_
18-4	2473-2477	many	substance[146]	new[146]	_	_
18-5	2478-2483	other	substance[146]	new[146]	_	_
18-6	2484-2499	polysaccharides	substance[146]	new[146]	_	_
18-7	2500-2501	,	_	_	_	_
18-8	2502-2504	it	abstract	giv	coref	31-41[244_0]
18-9	2505-2513	presents	_	_	_	_
18-10	2514-2518	some	abstract[148]	new[148]	coref	19-16[162_148]
18-11	2519-2532	disadvantages	abstract[148]	new[148]	_	_
18-12	2533-2537	such	abstract[148]	new[148]	_	_
18-13	2538-2540	as	abstract[148]	new[148]	_	_
18-14	2541-2545	poor	abstract[148]|abstract[149]	new[148]|giv[149]	coref	28-1[218_149]
18-15	2546-2556	mechanical	abstract[148]|abstract[149]	new[148]|giv[149]	_	_
18-16	2557-2567	properties	abstract[148]|abstract[149]	new[148]|giv[149]	_	_
18-17	2568-2569	,	abstract[148]|abstract[149]	new[148]|giv[149]	_	_
18-18	2570-2574	poor	abstract[148]|abstract[149]|substance[150]	new[148]|giv[149]|new[150]	_	_
18-19	2575-2585	solubility	abstract[148]|abstract[149]|substance[150]	new[148]|giv[149]|new[150]	_	_
18-20	2586-2588	in	abstract[148]|abstract[149]|substance[150]	new[148]|giv[149]|new[150]	_	_
18-21	2589-2601	conventional	abstract[148]|abstract[149]|substance[150]|substance[151]	new[148]|giv[149]|new[150]|new[151]	_	_
18-22	2602-2610	solvents	abstract[148]|abstract[149]|substance[150]|substance[151]	new[148]|giv[149]|new[150]|new[151]	_	_
18-23	2611-2612	,	abstract[148]|abstract[149]	new[148]|giv[149]	_	_
18-24	2613-2616	and	abstract[148]|abstract[149]	new[148]|giv[149]	_	_
18-25	2617-2621	poor	abstract[148]|abstract[149]|abstract[152]	new[148]|giv[149]|new[152]	coref	21-13[176_152]
18-26	2622-2631	stability	abstract[148]|abstract[149]|abstract[152]	new[148]|giv[149]|new[152]	_	_
18-27	2632-2634	in	abstract[148]|abstract[149]|abstract[152]	new[148]|giv[149]|new[152]	_	_
18-28	2635-2648	physiological	abstract[148]|abstract[149]|abstract[152]|abstract[153]	new[148]|giv[149]|new[152]|new[153]	_	_
18-29	2649-2654	media	abstract[148]|abstract[149]|abstract[152]|abstract[153]	new[148]|giv[149]|new[152]|new[153]	_	_
18-30	2655-2658	due	abstract[148]|abstract[149]|abstract[152]|abstract[153]	new[148]|giv[149]|new[152]|new[153]	_	_
18-31	2659-2661	to	_	_	_	_
18-32	2662-2665	the	abstract[154]	new[154]	_	_
18-33	2666-2670	high	abstract[154]	new[154]	_	_
18-34	2671-2677	amount	abstract[154]	new[154]	_	_
18-35	2678-2680	of	abstract[154]	new[154]	_	_
18-36	2681-2689	hydrogen	abstract[154]|substance|abstract[156]	new[154]|new|new[156]	_	_
18-37	2690-2697	bonding	abstract[154]|abstract[156]	new[154]|new[156]	_	_
18-38	2698-2699	.	_	_	_	_

#Text=Many studies addressed the physicochemical attributes of nanocomposite polymers thanks to their effectiveness in overcoming the disadvantages of naturally occurring polymers .
19-1	2700-2704	Many	event[157]	new[157]	coref	31-13[236_157]
19-2	2705-2712	studies	event[157]	new[157]	_	_
19-3	2713-2722	addressed	_	_	_	_
19-4	2723-2726	the	abstract[158]	new[158]	_	_
19-5	2727-2742	physicochemical	abstract[158]	new[158]	_	_
19-6	2743-2753	attributes	abstract[158]	new[158]	_	_
19-7	2754-2756	of	abstract[158]	new[158]	_	_
19-8	2757-2770	nanocomposite	abstract[158]|person	new[158]|new	coref	32-20
19-9	2771-2779	polymers	abstract[158]|substance	new[158]|giv	coref	19-21
19-10	2780-2786	thanks	abstract[158]	new[158]	_	_
19-11	2787-2789	to	abstract[158]	new[158]	_	_
19-12	2790-2795	their	abstract[158]|abstract[161]	new[158]|new[161]	_	_
19-13	2796-2809	effectiveness	abstract[158]|abstract[161]	new[158]|new[161]	_	_
19-14	2810-2812	in	_	_	_	_
19-15	2813-2823	overcoming	_	_	_	_
19-16	2824-2827	the	abstract[162]	giv[162]	_	_
19-17	2828-2841	disadvantages	abstract[162]	giv[162]	_	_
19-18	2842-2844	of	_	_	_	_
19-19	2845-2854	naturally	_	_	_	_
19-20	2855-2864	occurring	_	_	_	_
19-21	2865-2873	polymers	substance	giv	_	_
19-22	2874-2875	.	_	_	_	_

#Text=Our group investigated the use of nanocomposites based on graphene oxide and chitosan for applications in tissue engineering .
20-1	2876-2879	Our	person|organization[165]	acc|new[165]	_	_
20-2	2880-2885	group	organization[165]	new[165]	_	_
20-3	2886-2898	investigated	_	_	_	_
20-4	2899-2902	the	abstract[166]	new[166]	_	_
20-5	2903-2906	use	abstract[166]	new[166]	_	_
20-6	2907-2909	of	abstract[166]	new[166]	_	_
20-7	2910-2924	nanocomposites	abstract[166]|object	new[166]|new	coref	21-23[178_0]
20-8	2925-2930	based	_	_	_	_
20-9	2931-2933	on	_	_	_	_
20-10	2934-2942	graphene	abstract|substance[169]	new|new[169]	_	_
20-11	2943-2948	oxide	substance[169]	new[169]	_	_
20-12	2949-2952	and	_	_	_	_
20-13	2953-2961	chitosan	substance	giv	coref	21-25
20-14	2962-2965	for	_	_	_	_
20-15	2966-2978	applications	abstract[171]	giv[171]	coref	24-5[202_171]
20-16	2979-2981	in	abstract[171]	giv[171]	_	_
20-17	2982-2988	tissue	abstract[171]|object|abstract[173]	giv[171]|giv|giv[173]	coref|coref|coref|coref	33-23|33-23[267_173]|33-23|33-23[267_173]
20-18	2989-3000	engineering	abstract[171]|abstract[173]	giv[171]|giv[173]	_	_
20-19	3001-3002	.	_	_	_	_

#Text=Even with the nanofillers , there is still a need to achieve better mechanical and thermal stability combined with higher biocompatibility in nanocomposites of chitosan and carbon nanomaterials .
21-1	3003-3007	Even	object[174]	giv[174]	_	_
21-2	3008-3012	with	object[174]	giv[174]	_	_
21-3	3013-3016	the	object[174]	giv[174]	_	_
21-4	3017-3028	nanofillers	object[174]	giv[174]	_	_
21-5	3029-3030	,	_	_	_	_
21-6	3031-3036	there	_	_	_	_
21-7	3037-3039	is	_	_	_	_
21-8	3040-3045	still	_	_	_	_
21-9	3046-3047	a	abstract[175]	new[175]	_	_
21-10	3048-3052	need	abstract[175]	new[175]	_	_
21-11	3053-3055	to	_	_	_	_
21-12	3056-3063	achieve	_	_	_	_
21-13	3064-3070	better	abstract[176]	giv[176]	_	_
21-14	3071-3081	mechanical	abstract[176]	giv[176]	_	_
21-15	3082-3085	and	abstract[176]	giv[176]	_	_
21-16	3086-3093	thermal	abstract[176]	giv[176]	_	_
21-17	3094-3103	stability	abstract[176]	giv[176]	_	_
21-18	3104-3112	combined	_	_	_	_
21-19	3113-3117	with	_	_	_	_
21-20	3118-3124	higher	abstract[177]	giv[177]	coref	34-14[0_177]
21-21	3125-3141	biocompatibility	abstract[177]	giv[177]	_	_
21-22	3142-3144	in	abstract[177]	giv[177]	_	_
21-23	3145-3159	nanocomposites	abstract[177]|object[178]	giv[177]|giv[178]	_	_
21-24	3160-3162	of	abstract[177]|object[178]	giv[177]|giv[178]	_	_
21-25	3163-3171	chitosan	abstract[177]|object[178]|substance	giv[177]|giv[178]|giv	coref	27-8
21-26	3172-3175	and	abstract[177]|object[178]	giv[177]|giv[178]	_	_
21-27	3176-3182	carbon	abstract[177]|object[178]|object[180]	giv[177]|giv[178]|new[180]	_	_
21-28	3183-3196	nanomaterials	abstract[177]|object[178]|object[180]	giv[177]|giv[178]|new[180]	_	_
21-29	3197-3198	.	_	_	_	_

#Text=Carbon nano-onions ( CNOs ) are multi-shell fullerenes of 5 to 10 nm , discovered by Ugarte in 1992 upon impacting carbon nanostructures with an electron beam through a TEM experiment .
22-1	3199-3205	Carbon	person|object[182]	new|new[182]	appos|appos	22-4[0_182]|22-4[0_182]
22-2	3206-3217	nano-onions	object[182]	new[182]	_	_
22-3	3218-3219	(	_	_	_	_
22-4	3220-3224	CNOs	object	giv	coref	22-7[184_0]
22-5	3225-3226	)	_	_	_	_
22-6	3227-3230	are	_	_	_	_
22-7	3231-3242	multi-shell	object[184]	giv[184]	coref	23-6[0_184]
22-8	3243-3253	fullerenes	object[184]	giv[184]	_	_
22-9	3254-3256	of	object[184]	giv[184]	_	_
22-10	3257-3258	5	object[184]|quantity	giv[184]|new	_	_
22-11	3259-3261	to	object[184]	giv[184]	_	_
22-12	3262-3264	10	object[184]|quantity[186]	giv[184]|new[186]	_	_
22-13	3265-3267	nm	object[184]|quantity[186]	giv[184]|new[186]	_	_
22-14	3268-3269	,	_	_	_	_
22-15	3270-3280	discovered	_	_	_	_
22-16	3281-3283	by	_	_	_	_
22-17	3284-3290	Ugarte	person	new	_	_
22-18	3291-3293	in	_	_	_	_
22-19	3294-3298	1992	time	new	_	_
22-20	3299-3303	upon	_	_	_	_
22-21	3304-3313	impacting	_	_	_	_
22-22	3314-3320	carbon	substance|object[190]	new|new[190]	_	_
22-23	3321-3335	nanostructures	object[190]	new[190]	_	_
22-24	3336-3340	with	_	_	_	_
22-25	3341-3343	an	object[192]	new[192]	_	_
22-26	3344-3352	electron	substance|object[192]	new|new[192]	_	_
22-27	3353-3357	beam	object[192]	new[192]	_	_
22-28	3358-3365	through	object[192]	new[192]	_	_
22-29	3366-3367	a	object[192]|object[194]	new[192]|new[194]	_	_
22-30	3368-3371	TEM	object[192]|place|object[194]	new[192]|new|new[194]	_	_
22-31	3372-3382	experiment	object[192]|object[194]	new[192]|new[194]	_	_
22-32	3383-3384	.	_	_	_	_

#Text=For the chemical derivatization of CNOs , various synthetic routes were applied , introducing new functional groups that increase their application possibilities .
23-1	3385-3388	For	_	_	_	_
23-2	3389-3392	the	abstract[195]	new[195]	_	_
23-3	3393-3401	chemical	abstract[195]	new[195]	_	_
23-4	3402-3416	derivatization	abstract[195]	new[195]	_	_
23-5	3417-3419	of	abstract[195]	new[195]	_	_
23-6	3420-3424	CNOs	abstract[195]|substance	new[195]|giv	coref	25-1
23-7	3425-3426	,	_	_	_	_
23-8	3427-3434	various	abstract[197]	new[197]	_	_
23-9	3435-3444	synthetic	abstract[197]	new[197]	_	_
23-10	3445-3451	routes	abstract[197]	new[197]	_	_
23-11	3452-3456	were	_	_	_	_
23-12	3457-3464	applied	_	_	_	_
23-13	3465-3466	,	_	_	_	_
23-14	3467-3478	introducing	_	_	_	_
23-15	3479-3482	new	person[198]	giv[198]	ana	23-20[0_198]
23-16	3483-3493	functional	person[198]	giv[198]	_	_
23-17	3494-3500	groups	person[198]	giv[198]	_	_
23-18	3501-3505	that	_	_	_	_
23-19	3506-3514	increase	_	_	_	_
23-20	3515-3520	their	person|abstract[201]	giv|new[201]	_	_
23-21	3521-3532	application	abstract|abstract[201]	new|new[201]	coref	33-19[265_0]
23-22	3533-3546	possibilities	abstract[201]	new[201]	_	_
23-23	3547-3548	.	_	_	_	_

#Text=Some potential uses include optical applications , catalysis , and gas storage .
24-1	3549-3553	Some	_	_	_	_
24-2	3554-3563	potential	_	_	_	_
24-3	3564-3568	uses	_	_	_	_
24-4	3569-3576	include	_	_	_	_
24-5	3577-3584	optical	abstract[202]	giv[202]	coref	25-6[208_202]
24-6	3585-3597	applications	abstract[202]	giv[202]	_	_
24-7	3598-3599	,	abstract[202]	giv[202]	_	_
24-8	3600-3609	catalysis	abstract[202]|substance	giv[202]|new	_	_
24-9	3610-3611	,	abstract[202]	giv[202]	_	_
24-10	3612-3615	and	abstract[202]	giv[202]	_	_
24-11	3616-3619	gas	abstract[202]|substance|abstract[205]	giv[202]|new|new[205]	_	_
24-12	3620-3627	storage	abstract[202]|abstract[205]	giv[202]|new[205]	_	_
24-13	3628-3629	.	_	_	_	_

#Text=CNOs are also useful in photovoltaic and fuel cell applications .
25-1	3630-3634	CNOs	object	giv	coref	28-8
25-2	3635-3638	are	_	_	_	_
25-3	3639-3643	also	_	_	_	_
25-4	3644-3650	useful	_	_	_	_
25-5	3651-3653	in	_	_	_	_
25-6	3654-3666	photovoltaic	abstract[208]	giv[208]	ana	26-1[0_208]
25-7	3667-3670	and	abstract[208]	giv[208]	_	_
25-8	3671-3675	fuel	abstract[208]	giv[208]	_	_
25-9	3676-3680	cell	object|abstract[208]	giv|giv[208]	coref	31-34
25-10	3681-3693	applications	abstract[208]	giv[208]	_	_
25-11	3694-3695	.	_	_	_	_

#Text=They demonstrated a superior lubrication ability compared to conventional lubricants .
26-1	3696-3700	They	abstract	giv	coref	29-14[229_0]
26-2	3701-3713	demonstrated	_	_	_	_
26-3	3714-3715	a	abstract[211]	new[211]	_	_
26-4	3716-3724	superior	abstract[211]	new[211]	_	_
26-5	3725-3736	lubrication	substance|abstract[211]	new|new[211]	_	_
26-6	3737-3744	ability	abstract[211]	new[211]	_	_
26-7	3745-3753	compared	_	_	_	_
26-8	3754-3756	to	_	_	_	_
26-9	3757-3769	conventional	abstract[212]	new[212]	_	_
26-10	3770-3780	lubricants	abstract[212]	new[212]	_	_
26-11	3781-3782	.	_	_	_	_

#Text=However , there are few reports of CS and CNO composites in the literature .
27-1	3783-3790	However	_	_	_	_
27-2	3791-3792	,	_	_	_	_
27-3	3793-3798	there	_	_	_	_
27-4	3799-3802	are	_	_	_	_
27-5	3803-3806	few	abstract[213]	new[213]	_	_
27-6	3807-3814	reports	abstract[213]	new[213]	_	_
27-7	3815-3817	of	abstract[213]	new[213]	_	_
27-8	3818-3820	CS	abstract[213]|abstract	new[213]|giv	coref	28-18
27-9	3821-3824	and	abstract[213]	new[213]	_	_
27-10	3825-3828	CNO	abstract[213]|abstract|object[216]	new[213]|new|giv[216]	coref|coref	28-5[0_216]|28-5[0_216]
27-11	3829-3839	composites	abstract[213]|object[216]	new[213]|giv[216]	_	_
27-12	3840-3842	in	abstract[213]|object[216]	new[213]|giv[216]	_	_
27-13	3843-3846	the	abstract[213]|object[216]|abstract[217]	new[213]|giv[216]|new[217]	coref	29-4[0_217]
27-14	3847-3857	literature	abstract[213]|object[216]|abstract[217]	new[213]|giv[216]|new[217]	_	_
27-15	3858-3859	.	_	_	_	_

#Text=The electrochemical properties of composites consisting of CNOs and poly(diallyl dimethylammonium chloride ) ( PDDA ) or chitosan ( CS ) were reported .
28-1	3860-3863	The	abstract[218]	giv[218]	_	_
28-2	3864-3879	electrochemical	abstract[218]	giv[218]	_	_
28-3	3880-3890	properties	abstract[218]	giv[218]	_	_
28-4	3891-3893	of	abstract[218]	giv[218]	_	_
28-5	3894-3904	composites	abstract[218]|object	giv[218]|giv	_	_
28-6	3905-3915	consisting	_	_	_	_
28-7	3916-3918	of	_	_	_	_
28-8	3919-3923	CNOs	substance	giv	appos	28-10[221_0]
28-9	3924-3927	and	_	_	_	_
28-10	3928-3940	poly(diallyl	substance[221]	giv[221]	coref	30-12[0_221]
28-11	3941-3957	dimethylammonium	substance[221]	giv[221]	_	_
28-12	3958-3966	chloride	substance[221]	giv[221]	_	_
28-13	3967-3968	)	_	_	_	_
28-14	3969-3970	(	_	_	_	_
28-15	3971-3975	PDDA	_	_	_	_
28-16	3976-3977	)	_	_	_	_
28-17	3978-3980	or	_	_	_	_
28-18	3981-3989	chitosan	substance	giv	coref	28-20
28-19	3990-3991	(	_	_	_	_
28-20	3992-3994	CS	abstract	giv	coref	29-8
28-21	3995-3996	)	_	_	_	_
28-22	3997-4001	were	_	_	_	_
28-23	4002-4010	reported	_	_	_	_
28-24	4011-4012	.	_	_	_	_

#Text=The lack of literature regarding nanocomposites of CS and oxidized ( ox-)CNOs for biomedical applications is evident .
29-1	4013-4016	The	abstract[224]	new[224]	_	_
29-2	4017-4021	lack	abstract[224]	new[224]	_	_
29-3	4022-4024	of	abstract[224]	new[224]	_	_
29-4	4025-4035	literature	abstract[224]|abstract	new[224]|giv	_	_
29-5	4036-4045	regarding	_	_	_	_
29-6	4046-4060	nanocomposites	substance[226]	new[226]	coref	33-12[263_226]
29-7	4061-4063	of	substance[226]	new[226]	_	_
29-8	4064-4066	CS	substance[226]|substance	new[226]|giv	_	_
29-9	4067-4070	and	substance[226]	new[226]	_	_
29-10	4071-4079	oxidized	substance[226]	new[226]	_	_
29-11	4080-4081	(	_	_	_	_
29-12	4082-4090	ox-)CNOs	abstract[228]	new[228]	_	_
29-13	4091-4094	for	abstract[228]	new[228]	_	_
29-14	4095-4105	biomedical	abstract[228]|abstract[229]	new[228]|giv[229]	ana	31-1[0_229]
29-15	4106-4118	applications	abstract[228]|abstract[229]	new[228]|giv[229]	_	_
29-16	4119-4121	is	_	_	_	_
29-17	4122-4129	evident	_	_	_	_
29-18	4130-4131	.	_	_	_	_

#Text=Very few studies were carried out to determine the cytotoxicity of CNOs .
30-1	4132-4136	Very	event[230]	new[230]	_	_
30-2	4137-4140	few	event[230]	new[230]	_	_
30-3	4141-4148	studies	event[230]	new[230]	_	_
30-4	4149-4153	were	_	_	_	_
30-5	4154-4161	carried	_	_	_	_
30-6	4162-4165	out	_	_	_	_
30-7	4166-4168	to	_	_	_	_
30-8	4169-4178	determine	_	_	_	_
30-9	4179-4182	the	abstract[231]	new[231]	_	_
30-10	4183-4195	cytotoxicity	abstract[231]	new[231]	_	_
30-11	4196-4198	of	abstract[231]	new[231]	_	_
30-12	4199-4203	CNOs	abstract[231]|abstract	new[231]|giv	_	_
30-13	4204-4205	.	_	_	_	_

#Text=They were even used for the treatment of cancer ; however , many more studies are still required to show whether they are toxic or if , on the contrary , they promote cell adhesion and proliferation , while facilitating the recognition and permanence of scaffolds in animal tissues without immune responses .
31-1	4206-4210	They	abstract	giv	ana	31-22
31-2	4211-4215	were	_	_	_	_
31-3	4216-4220	even	_	_	_	_
31-4	4221-4225	used	_	_	_	_
31-5	4226-4229	for	_	_	_	_
31-6	4230-4233	the	event[234]	new[234]	_	_
31-7	4234-4243	treatment	event[234]	new[234]	_	_
31-8	4244-4246	of	event[234]	new[234]	_	_
31-9	4247-4253	cancer	event[234]|abstract	new[234]|new	_	_
31-10	4254-4255	;	_	_	_	_
31-11	4256-4263	however	_	_	_	_
31-12	4264-4265	,	_	_	_	_
31-13	4266-4270	many	event[236]	giv[236]	coref	34-14[273_236]
31-14	4271-4275	more	event[236]	giv[236]	_	_
31-15	4276-4283	studies	event[236]	giv[236]	_	_
31-16	4284-4287	are	_	_	_	_
31-17	4288-4293	still	_	_	_	_
31-18	4294-4302	required	_	_	_	_
31-19	4303-4305	to	_	_	_	_
31-20	4306-4310	show	_	_	_	_
31-21	4311-4318	whether	_	_	_	_
31-22	4319-4323	they	abstract	giv	ana	31-32
31-23	4324-4327	are	_	_	_	_
31-24	4328-4333	toxic	_	_	_	_
31-25	4334-4336	or	_	_	_	_
31-26	4337-4339	if	_	_	_	_
31-27	4340-4341	,	_	_	_	_
31-28	4342-4344	on	_	_	_	_
31-29	4345-4348	the	abstract[238]	new[238]	_	_
31-30	4349-4357	contrary	abstract[238]	new[238]	_	_
31-31	4358-4359	,	_	_	_	_
31-32	4360-4364	they	abstract	giv	_	_
31-33	4365-4372	promote	_	_	_	_
31-34	4373-4377	cell	place|abstract[241]|abstract[242]	giv|giv[241]|giv[242]	_	_
31-35	4378-4386	adhesion	abstract[241]|abstract[242]	giv[241]|giv[242]	_	_
31-36	4387-4390	and	abstract[242]	giv[242]	_	_
31-37	4391-4404	proliferation	abstract[242]|event	giv[242]|giv	_	_
31-38	4405-4406	,	_	_	_	_
31-39	4407-4412	while	_	_	_	_
31-40	4413-4425	facilitating	_	_	_	_
31-41	4426-4429	the	abstract[244]	giv[244]	_	_
31-42	4430-4441	recognition	abstract[244]	giv[244]	_	_
31-43	4442-4445	and	_	_	_	_
31-44	4446-4456	permanence	abstract[245]	new[245]	_	_
31-45	4457-4459	of	abstract[245]	new[245]	_	_
31-46	4460-4469	scaffolds	abstract[245]|object[246]	new[245]|new[246]	_	_
31-47	4470-4472	in	abstract[245]|object[246]	new[245]|new[246]	_	_
31-48	4473-4479	animal	abstract[245]|object[246]|animal|place[248]	new[245]|new[246]|new|new[248]	_	_
31-49	4480-4487	tissues	abstract[245]|object[246]|place[248]	new[245]|new[246]|new[248]	_	_
31-50	4488-4495	without	abstract[245]|object[246]	new[245]|new[246]	_	_
31-51	4496-4502	immune	abstract[245]|object[246]|abstract[249]	new[245]|new[246]|new[249]	ana	32-8[0_249]
31-52	4503-4512	responses	abstract[245]|object[246]|abstract[249]	new[245]|new[246]|new[249]	_	_
31-53	4513-4514	.	_	_	_	_

#Text=There is a lack of information on their characterization including the physical , chemical , and mechanical evaluation of nanocomposite films based on CS/poly(vinyl alcohol ) ( PVA)/ox-CNO , together with biological tests in vitro and in vivo .
32-1	4515-4520	There	_	_	_	_
32-2	4521-4523	is	_	_	_	_
32-3	4524-4525	a	abstract[250]	new[250]	_	_
32-4	4526-4530	lack	abstract[250]	new[250]	_	_
32-5	4531-4533	of	abstract[250]	new[250]	_	_
32-6	4534-4545	information	abstract[250]|abstract	new[250]|new	coref	33-9[262_0]
32-7	4546-4548	on	abstract[250]	new[250]	_	_
32-8	4549-4554	their	abstract[250]|abstract|abstract[253]	new[250]|giv|new[253]	_	_
32-9	4555-4571	characterization	abstract[250]|abstract[253]	new[250]|new[253]	_	_
32-10	4572-4581	including	abstract[250]|abstract[253]	new[250]|new[253]	_	_
32-11	4582-4585	the	abstract[250]|abstract[253]|abstract[254]	new[250]|new[253]|new[254]	_	_
32-12	4586-4594	physical	abstract[250]|abstract[253]|abstract[254]	new[250]|new[253]|new[254]	_	_
32-13	4595-4596	,	abstract[250]|abstract[253]|abstract[254]	new[250]|new[253]|new[254]	_	_
32-14	4597-4605	chemical	abstract[250]|abstract[253]|abstract[254]	new[250]|new[253]|new[254]	_	_
32-15	4606-4607	,	abstract[250]|abstract[253]|abstract[254]	new[250]|new[253]|new[254]	_	_
32-16	4608-4611	and	abstract[250]|abstract[253]|abstract[254]	new[250]|new[253]|new[254]	_	_
32-17	4612-4622	mechanical	abstract[250]|abstract[253]|abstract[254]	new[250]|new[253]|new[254]	_	_
32-18	4623-4633	evaluation	abstract[250]|abstract[253]|abstract[254]	new[250]|new[253]|new[254]	_	_
32-19	4634-4636	of	abstract[250]|abstract[253]|abstract[254]	new[250]|new[253]|new[254]	_	_
32-20	4637-4650	nanocomposite	abstract[250]|abstract[253]|abstract[254]|person|object[256]	new[250]|new[253]|new[254]|giv|new[256]	coref|coref	34-6[269_256]|34-6[269_256]
32-21	4651-4656	films	abstract[250]|abstract[253]|abstract[254]|object[256]	new[250]|new[253]|new[254]|new[256]	_	_
32-22	4657-4662	based	_	_	_	_
32-23	4663-4665	on	_	_	_	_
32-24	4666-4679	CS/poly(vinyl	substance|substance[258]	new|new[258]	_	_
32-25	4680-4687	alcohol	substance[258]	new[258]	_	_
32-26	4688-4689	)	_	_	_	_
32-27	4690-4691	(	_	_	_	_
32-28	4692-4703	PVA)/ox-CNO	_	_	_	_
32-29	4704-4705	,	_	_	_	_
32-30	4706-4714	together	_	_	_	_
32-31	4715-4719	with	_	_	_	_
32-32	4720-4730	biological	abstract[259]	new[259]	_	_
32-33	4731-4736	tests	abstract[259]	new[259]	_	_
32-34	4737-4739	in	abstract[259]	new[259]	_	_
32-35	4740-4745	vitro	abstract[259]	new[259]	_	_
32-36	4746-4749	and	_	_	_	_
32-37	4750-4752	in	_	_	_	_
32-38	4753-4757	vivo	_	_	_	_
32-39	4758-4759	.	_	_	_	_

#Text=The results of this investigation will allow collecting toxicological information for these nanocomposites , as well as evaluating their possible application in tissue engineering .
33-1	4760-4763	The	abstract[260]	giv[260]	_	_
33-2	4764-4771	results	abstract[260]	giv[260]	_	_
33-3	4772-4774	of	abstract[260]	giv[260]	_	_
33-4	4775-4779	this	abstract[260]|abstract[261]	giv[260]|new[261]	_	_
33-5	4780-4793	investigation	abstract[260]|abstract[261]	giv[260]|new[261]	_	_
33-6	4794-4798	will	_	_	_	_
33-7	4799-4804	allow	_	_	_	_
33-8	4805-4815	collecting	_	_	_	_
33-9	4816-4829	toxicological	abstract[262]	giv[262]	_	_
33-10	4830-4841	information	abstract[262]	giv[262]	_	_
33-11	4842-4845	for	abstract[262]	giv[262]	_	_
33-12	4846-4851	these	abstract[262]|object[263]	giv[262]|giv[263]	ana	33-19[0_263]
33-13	4852-4866	nanocomposites	abstract[262]|object[263]	giv[262]|giv[263]	_	_
33-14	4867-4868	,	_	_	_	_
33-15	4869-4871	as	_	_	_	_
33-16	4872-4876	well	_	_	_	_
33-17	4877-4879	as	_	_	_	_
33-18	4880-4890	evaluating	_	_	_	_
33-19	4891-4896	their	object|abstract[265]	giv|giv[265]	_	_
33-20	4897-4905	possible	abstract[265]	giv[265]	_	_
33-21	4906-4917	application	abstract[265]	giv[265]	_	_
33-22	4918-4920	in	abstract[265]	giv[265]	_	_
33-23	4921-4927	tissue	abstract[265]|object|abstract[267]	giv[265]|giv|giv[267]	_	_
33-24	4928-4939	engineering	abstract[265]|abstract[267]	giv[265]|giv[267]	_	_
33-25	4940-4941	.	_	_	_	_

#Text=Therefore , this research investigates nanocomposite films of PVA/CS reinforced with ox-CNOs for biocompatibility studies at 90 days of subdermal implantation in biomodel skin .
34-1	4942-4951	Therefore	_	_	_	_
34-2	4952-4953	,	_	_	_	_
34-3	4954-4958	this	abstract[268]	new[268]	_	_
34-4	4959-4967	research	abstract[268]	new[268]	_	_
34-5	4968-4980	investigates	_	_	_	_
34-6	4981-4994	nanocomposite	object[269]	giv[269]	_	_
34-7	4995-5000	films	object[269]	giv[269]	_	_
34-8	5001-5003	of	object[269]	giv[269]	_	_
34-9	5004-5010	PVA/CS	object[269]|substance	giv[269]|new	_	_
34-10	5011-5021	reinforced	_	_	_	_
34-11	5022-5026	with	_	_	_	_
34-12	5027-5034	ox-CNOs	object	new	_	_
34-13	5035-5038	for	_	_	_	_
34-14	5039-5055	biocompatibility	abstract|event[273]	giv|giv[273]	_	_
34-15	5056-5063	studies	event[273]	giv[273]	_	_
34-16	5064-5066	at	event[273]	giv[273]	_	_
34-17	5067-5069	90	event[273]|time[274]	giv[273]|new[274]	_	_
34-18	5070-5074	days	event[273]|time[274]	giv[273]|new[274]	_	_
34-19	5075-5077	of	event[273]|time[274]	giv[273]|new[274]	_	_
34-20	5078-5087	subdermal	event[273]|time[274]|object[275]	giv[273]|new[274]|new[275]	_	_
34-21	5088-5100	implantation	event[273]|time[274]|object[275]	giv[273]|new[274]|new[275]	_	_
34-22	5101-5103	in	event[273]|time[274]|object[275]	giv[273]|new[274]|new[275]	_	_
34-23	5104-5112	biomodel	event[273]|time[274]|object[275]|object[276]	giv[273]|new[274]|new[275]|new[276]	_	_
34-24	5113-5117	skin	event[273]|time[274]|object[275]|object[276]	giv[273]|new[274]|new[275]|new[276]	_	_
34-25	5118-5119	.	_	_	_	_
